PT1107746E - Metodos para a utilizacao e composicoes que compreendem os inibidores da retoma da dopamina - Google Patents

Metodos para a utilizacao e composicoes que compreendem os inibidores da retoma da dopamina

Info

Publication number
PT1107746E
PT1107746E PT99945137T PT99945137T PT1107746E PT 1107746 E PT1107746 E PT 1107746E PT 99945137 T PT99945137 T PT 99945137T PT 99945137 T PT99945137 T PT 99945137T PT 1107746 E PT1107746 E PT 1107746E
Authority
PT
Portugal
Prior art keywords
disorders
disorder
desmethylsibutramine
didesmethylsibutramine
optionally
Prior art date
Application number
PT99945137T
Other languages
English (en)
Portuguese (pt)
Inventor
Thomas P Jerussi
Chrisantha H Senanayake
Qun K Fang
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of PT1107746E publication Critical patent/PT1107746E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Information Transfer Systems (AREA)
PT99945137T 1998-08-24 1999-08-23 Metodos para a utilizacao e composicoes que compreendem os inibidores da retoma da dopamina PT1107746E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9766598P 1998-08-24 1998-08-24
US9930698P 1998-09-02 1998-09-02
US09/372,158 US6331571B1 (en) 1998-08-24 1999-08-11 Methods of treating and preventing attention deficit disorders

Publications (1)

Publication Number Publication Date
PT1107746E true PT1107746E (pt) 2005-03-31

Family

ID=27378425

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99945137T PT1107746E (pt) 1998-08-24 1999-08-23 Metodos para a utilizacao e composicoes que compreendem os inibidores da retoma da dopamina

Country Status (20)

Country Link
US (3) US6331571B1 (enExample)
EP (2) EP1475086A3 (enExample)
JP (1) JP2002523366A (enExample)
KR (3) KR20080011354A (enExample)
CN (1) CN100415222C (enExample)
AT (1) ATE279184T1 (enExample)
AU (2) AU772303B2 (enExample)
CA (1) CA2341441C (enExample)
CZ (1) CZ2001677A3 (enExample)
DE (1) DE69921157T2 (enExample)
DK (1) DK1107746T3 (enExample)
ES (1) ES2226435T3 (enExample)
HU (1) HUP0103408A3 (enExample)
ID (1) ID28638A (enExample)
IL (2) IL141531A0 (enExample)
NO (1) NO20010943L (enExample)
NZ (1) NZ510193A (enExample)
PL (1) PL200264B1 (enExample)
PT (1) PT1107746E (enExample)
WO (1) WO2000010551A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) * 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
SK12992001A3 (sk) * 1999-03-19 2002-03-05 Knoll Gmbh Použitie zlúčeniny a farmaceutická kompozícia ju obsahujúca
ATE305788T1 (de) * 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc (s,s)-reboxetin zur behandlung von inkontinenz
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002036540A2 (en) * 2000-11-02 2002-05-10 Torrent Pharmaceuticals Ltd PROCESS FOR PREPARATION OF β-PHENETHYLAMINE DERIVATIVE
US20020115727A1 (en) * 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
WO2003065970A2 (en) * 2001-02-20 2003-08-14 Royal College Of Surgeons Ie Treatment of fibromyalgia and related fatigue syndromes using pindolol
DE10142666A1 (de) * 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
EP1513529B1 (en) * 2002-05-30 2011-12-14 NeuroSearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
WO2004019892A2 (en) * 2002-08-30 2004-03-11 Watson Pharmaceuticals, Inc. Drug delivery system for treating urinary incontinence
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050228052A1 (en) * 2004-01-29 2005-10-13 Barberich Timothy J Methods of treating, preventing and managing a sleep disorder using (S)-didesmethylsibutramine
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
ATE454140T1 (de) * 2004-02-18 2010-01-15 Sepracor Inc Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
US20050266085A1 (en) * 2004-05-28 2005-12-01 Warner Kevin S Gelled emulsion and microemulsion formulations for dermal drug delivery
KR100618176B1 (ko) * 2004-12-02 2006-09-01 휴먼팜 주식회사 시부트라민 주석산염, 이의 제조 방법 및 이를 포함하는약학적 조성물
WO2006067060A2 (en) * 2004-12-22 2006-06-29 Ciba Specialty Chemicals Holding Inc. Enantioselective synthesis of a sterically hindered amine
KR20060080817A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 디카복실산염
KR20060080818A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 술폰산염
WO2006073292A1 (en) * 2005-01-06 2006-07-13 Cj Corporation Inorganic acid salts of sibutramine
KR20060093564A (ko) * 2005-02-22 2006-08-25 종근당바이오 주식회사 무수 시부트라민 말산염 및 이의 제조 방법
KR100632470B1 (ko) * 2005-02-25 2006-10-12 민연식 결정성 시부트라민 캄실레이트염과 이의 제조방법
US20060240101A1 (en) * 2005-04-22 2006-10-26 Shubha Chungi Orally disintegrating pharmaceutical tablet formulations of olanzapine
US20090286804A1 (en) * 2005-06-17 2009-11-19 Pfizer Inc Metabolites of 1-[6-(1-ethyl-1-hydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1-yl)-benzyl]-pyrrolidin-2-one as seratonin receptor antagonists
ATE501143T1 (de) * 2006-03-10 2011-03-15 Univ New York State Res Found Homotropane mit zns-aktivität
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
JP2010518167A (ja) * 2007-02-12 2010-05-27 ディーエムアイ バイオサイエンシズ インコーポレイテッド 併存する早漏及び勃起障害の治療
US20080261991A1 (en) * 2007-02-12 2008-10-23 Dmi Biosciences, Inc. Reducing Side Effects of Tramadol
US20110244059A1 (en) * 2008-08-20 2011-10-06 The University Of Medicine And Dentistry Of New Jersey Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor
US20120053172A1 (en) 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
WO2010126970A1 (en) * 2009-04-28 2010-11-04 Optmed, Inc. Methods for treating and preventing erectile dysfunction
MX353096B (es) 2010-08-19 2017-12-19 Buck Institute For Age Res Star Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
CN113908295B (zh) * 2021-11-12 2023-07-21 郑州大学第一附属医院 一种阿普唑仑包合物及其制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155670A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3155669A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 2, 4, 8-triaza-spiro (4, 5) dec-2-enes
US3471515A (en) 1965-02-01 1969-10-07 Sandoz Ag (2-hydroxy-3-substituted aminopropoxy)indoles
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
GB1308191A (en) 1970-04-06 1973-02-21 Science Union & Cie Thiochroman derivatives and a process for preparing them
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE3008993A1 (de) 1980-03-08 1981-10-01 Röhm Pharma GmbH, 6100 Darmstadt Pharmazeutische zubereitungen
IE52768B1 (en) 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
ZA821577B (en) 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
JPS5940638A (ja) 1982-08-30 1984-03-06 Fuji Photo Film Co Ltd 直接ポジ用ハロゲン化銀写真乳剤
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
GB8909209D0 (en) 1989-04-22 1989-06-07 Wyeth John & Brother Ltd Piperazine derivatives
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5104899A (en) 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP0554172B1 (en) 1992-01-28 1998-04-29 Fujitsu Limited Color surface discharge type plasma display device
US5780051A (en) 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
AU4542893A (en) 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
CA2139000A1 (en) 1992-06-23 1994-01-06 James W. Young Methods and compositions for treating depression and other disorders using optically pure(+) sibutramine
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5459164A (en) 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9402641D0 (en) 1994-02-11 1994-04-06 Boots Co Plc Therapeutic agents
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ATE212860T1 (de) * 1994-09-19 2002-02-15 Fujisawa Pharmaceutical Co Eine neuartige medizinische verwendung eines 5ht 3-antagonisten
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9524681D0 (en) 1995-12-02 1996-01-31 Knoll Ag Chemical process
DE19632423A1 (de) 1996-08-12 1998-02-19 Merck Patent Gmbh Thienopyrimidine
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619962D0 (en) 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US5795880A (en) 1996-12-30 1998-08-18 Louisiana State University Medical Center Foundation Method and composition for treating obesity and related disorders in animals comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US6127363A (en) 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction

Also Published As

Publication number Publication date
JP2002523366A (ja) 2002-07-30
NO20010943L (no) 2001-04-23
AU2004200875A1 (en) 2004-04-01
CA2341441C (en) 2011-07-19
KR20060081725A (ko) 2006-07-13
US7071234B2 (en) 2006-07-04
ATE279184T1 (de) 2004-10-15
ES2226435T3 (es) 2005-03-16
AU5781799A (en) 2000-03-14
US20020188029A1 (en) 2002-12-12
HK1088238A1 (zh) 2006-11-03
CN100415222C (zh) 2008-09-03
KR20080011354A (ko) 2008-02-01
AU772303B2 (en) 2004-04-22
DE69921157D1 (de) 2004-11-18
EP1107746B1 (en) 2004-10-13
DE69921157T2 (de) 2006-02-02
NO20010943D0 (no) 2001-02-23
EP1107746A2 (en) 2001-06-20
HUP0103408A2 (hu) 2002-05-29
NZ510193A (en) 2003-09-26
CZ2001677A3 (cs) 2002-02-13
EP1475086A2 (en) 2004-11-10
KR20010085553A (ko) 2001-09-07
EP1475086A3 (en) 2006-12-13
US20030195261A1 (en) 2003-10-16
PL200264B1 (pl) 2008-12-31
AU2004200875B2 (en) 2006-10-26
WO2000010551A3 (en) 2000-09-21
PL346843A1 (en) 2002-02-25
CA2341441A1 (en) 2000-03-02
WO2000010551A2 (en) 2000-03-02
IL141531A (en) 2010-05-31
DK1107746T3 (da) 2005-02-14
KR100887008B1 (ko) 2009-03-04
IL141531A0 (en) 2002-05-23
HUP0103408A3 (en) 2002-10-28
US6331571B1 (en) 2001-12-18
US6538034B2 (en) 2003-03-25
CN1735407A (zh) 2006-02-15
ID28638A (id) 2001-06-21

Similar Documents

Publication Publication Date Title
NO20010943D0 (no) FremgangsmÕter for bruk og sammensetninger som innbefatter dopamin gjenopptaks inhibitorer
JP2007517059A5 (enExample)
BRPI0408005A (pt) composto, composição farmacêutica, métodos para inibir angiogênese, atividade de pde4 em uma célula e proliferação de célula de cáncer, para inibir ou reduzir polimerização de tubulina ou estabilidade de tubulina em uma célula, para tratar ou melhorar um distúrbio inflamatório, um cáncer e um distúrbio do sistema nervoso central e para visar, bloquear ou destruir a função de vasculatura de tumor e o endotélio de vasos de tumor
JP2003503450A5 (enExample)
SI1678172T1 (sl) AzabicikliŽŤne spojine za lajšanje boleŽŤine in zdravljenje motenj centralnega ĹľivŽŤnega sistema
JP2003524613A5 (enExample)
BR0206434A (pt) Composto, composição, e, métodos de tratamento ou de prevenção da recidiva de depressão, de um distúrbio de ansiedade, de um distúrbio da alimentação e de um distúrbio de incontinência urinária em um paciente
AR059206A1 (es) Uso de derivados de 4-imidazol para trastornos del snc
TWI312679B (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
JPH09505585A (ja) 酸化窒素合成の誘導を遮断するためのテトラヒドロビオプテリン利用の遮断
Tripathi et al. Management of psychiatric disorders in patients with Parkinson’s diseases
NO20041060L (no) Krystaller av hydroksynorefedrinderivat
Factor et al. Threatening auditory hallucinations and Cotard syndrome in Parkinson disease
RU2005123808A (ru) Производные карбостирила и ингибиторы обратного захвата серотонина для лечения эмоциональных расстройств
US20040266864A1 (en) Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl-and didesmethyl-metabolites of citalopram
Craine et al. Milnacipran ameliorates executive function impairments following frontal lobe traumatic brain injury in male rats: a multimodal behavioral assessment
CA2716966A1 (en) Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Cao et al. Fisetin Ameliorates Levodopa-Induced Dyskinesia in Experimental Model Parkinson's Disease: Role of Mitochondrial Activities and Monoamines Turnover
ANTIDEPRESSANT Pharmacologic characteristics of ideal antidepressants in the 21st century
De Ocampo et al. Sleep-related eating disorder in fraternal twins
Luckhaus et al. Venlafaxine withdrawal syndrome not prevented by maprotiline, but resolved by sertraline
TW200724138A (en) Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use
YAU Gerovital H3 (GH3), with 2% procaine as its active
US11065232B2 (en) Dihydrotetrabenazine for the treatment of anxiety and psychoses
Matsushita et al. Normalization of Padrenoceptor down-regulation by SSRI under chronic stress: A mechanism of action of prophylactic effects of antidepressant drugs